调节性 T 细胞消灭 cDC1 细胞会危及癌症免疫疗法。

IF 6.5 2区医学 Q1 IMMUNOLOGY

Oncoimmunology Pub Date : 2024-10-04 eCollection Date: 2024-01-01 DOI:10.1080/2162402X.2024.2412874

Peng Liu, Liwei Zhao, Guido Kroemer, Oliver Kepp

引用次数: 0

摘要

最近的研究结果表明，新抗原特异性细胞毒性1型调节性T（TR1）CD4 T细胞可以通过杀伤呈现与MHC II类结合的肿瘤抗原的1型常规树突状细胞（cDC1s）来颠覆癌症免疫疗法。这凸显了 cDC1s 在激发抗癌免疫力方面的重要性，但也带来了新的临床挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy.

Recent findings revealed that neoantigen-specific cytotoxic type 1 regulatory T (T_R1) CD4 T cells can subvert cancer immunotherapy by killing type 1 conventional dendritic cells (cDC1s) that present tumor antigens bound to MHC class II. This underlines the importance of cDC1s for eliciting anticancer immunity but poses a novel clinical challenge.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY

CiteScore

12.50

自引率

2.80%

发文量

276

审稿时长

24 weeks

期刊介绍： OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.